Pharmacokinetics of itraconazole oral solution in allogeneic bone marrow transplant patients receiving total body irradiation

Bone Marrow Transplantation

Volumn 21, Issue 12, 1998, Pages 1239-1243

  Michallet, M ^a   Persat, F ^b   Kranzhofer N ^a   Levron, J C ^c   Prat, C ^b   Belhabri, A ^a   Chwetzoff, E ^c   Le Moing, J P ^c   Fiere, D ^a   Piens, M A ^b  

^a EDOUARD HERRIOT HOSPITAL   (France)

^b UNIVERSITÉ LYON 1   (France)

^c Laboratoires Janssen Cilag   (France)

Author keywords

BMT; Itraconazole solution; Pharmacokinetics; TBI

Indexed keywords

ANTIFUNGAL AGENT; DRUG METABOLITE; HYDROXYITRACONAZOLE; ITRACONAZOLE;

ADULT; AGED; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; CLINICAL ARTICLE; DRUG BIOAVAILABILITY; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; WHOLE BODY RADIATION;

EID: 0031849023     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1701270     Document Type: Article

References (16)

1. Saag MS, Dismukes WE. Azole antifungal agents: emphasis on new triazoles. Antimicrob Agents Chemother 1988; 32: 1-8.
2. Denning DW, Tucker RM, Hanson LH, Stevens DA. Itraconazole in opportunistic mycoses: cryptococcosis and aspergillosis. J Antimicrob Chemother 1990; 28: 555-560.
3. Hardin TC, Graybill JR, Fetchick R et al. Pharmacokinetics of itraconazole following oral administration to normal volunteers. Antimicrob Agents Chemother 1988; 32: 1310-1313.
4. Boogaerts MA, Verhoef GE, Zachee P et al. Antifungal prophylaxis with itraconazole in prolonged neutropenia correlation with plasma levels. Mycoses 1989; 32 (Suppl.): 103-108.
5. Law D, Moore C, Denning D. Bio-assay for serum itraconazole concentrations using hydroxy-itraconazole standards. Antimicrob Agents Chemother 1994; 38: 1561-1566.
6. Levron JC, Le Moing JP, Chwetzoff E. Exemple de suivi thérapeutique actif: l'Itraconazole. Thérapie 1996; 51: 502-506.
7. Heykants J, Van Peer A, Van de Velde V et al. The clinical pharmacokinetics of itraconazole: an overview. Mycoses 1989; 32 (Suppl.): 67-87.
8. Barone JA, Koh JG, Bierman RH et al. Food interaction and steady-state pharmacokinetics of itraconazole capsules in healthy male volunteers. Antimicrob Agents Chemother 1993; 37: 778-784.
9. Van de Velde VJ, Van Peer AP, Heykants JJ et al. Effect of food on the pharmacokinetics of a new hydroxypropyl-betacyclodextrin formulation of itraconazole. Pharmacotherapy 1996; 16: 424-428.
10. Warnock DW, Turner A, Burke J. Comparison of high-performance liquid Chromatographic and microbiological methods for determination of itraconazole J Antimicrob Chemother 1988; 21: 93-100.
11. Shawe MT, Spector MH, Ladman AJ. Effects of cancer, radiotherapy and cytotoxic drugs on intestinal structure and function. Cancer Treatment Rev 1996; 6: 141-151.
12. Prentice AG, Warnock DW. Johnson SAN et al. Multiple dose pharmacokinetics of an oral solution of itraconazole in autologous bone marrow transplant recipients. J Antimicrob Chemother 1994; 34: 247-252.
13. Prentice AG, Warnock DW, Johnson SAN et al. Multiple dose pharmacokinetics of an oral solution of itraconazole in patients receiving chemotherapy for acute myeloid leukaemia. J Antimicrob Chemother 1995; 36: 657-663.
14. Persat F, Marzullo C, Guyotat D et al. Plasma itraconazole concentrations in neutropenic patients after repeated high-dose treatment. Eur J Cancer 1992; 28: 838-841.
15. Heykants J, Michiels M, Meuldermans W et al. The pharma-cokinetics of itraconazole in animals and man: an overview. In: RA Fromtling (ed). Recent Trends in the Discovery, Development and Evaluation of Antifungal Agents. JR Prous: Barcelona, 1987, pp 223-249.
16. Kintzel PE, Rollins CJ, Yee WJ, List AF. Low itraconazole serum concentrations following administration of itraconazole suspension to critically ill allogeneic bone marrow transplant recipients. Ann Pharmacother 1995; 29: 140-143.